Cansino Biologics, Inc. Class ASSE: 688185

"Cansino Biologics Inc."Semi-annual Report for 2026

Aug 28, 2026 · Issued by Cansino Biologics, Inc. Class A via Shanghai Stock Exchange

Semi-annual Report for 2026

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

Earlier from Cansino Biologics, Inc. Class A

"Cansino Biologics Inc."Announcement on Attending the 2026 Online Collective Reception Day for Investors of Listed Companies in Tianjin Jurisdiction and Semi-annual Performance BriefingAug 26
"Cansino Biologics Inc."Announcement on Abnormal Fluctuations in Stock TradingAug 22
"Cansino Biologics Inc."Announcement on Obtaining Drug Registration Certificate for Adsorbed Tetanus VaccineAug 21
"Cansino Biologics Inc."Announcement on Voluntary Disclosure of Acceptance of the Drug Registration Application for Adsorbed Tetanus, Diphtheria and Pertussis (Acellular, Five Components) Combined Vaccine (For Persons Aged 6 and Above)Aug 17

All Cansino Biologics, Inc. Class A news releases